NanoViricides starts Phase II DRC trial of oral NV-387 gummies in Bundibugyo Ebola patients
NNVC•NanoViricides began enrolling and dosing patients in a Phase II trial of oral NV-387 gummies for Ebola in the Democratic Republic of Congo. The initial dose run-in is intended to establish a tolerable approach for sicker patients; no results have been presented.
1. Trial begins
NanoViricides began enrolling and dosing patients in the Democratic Republic of Congo in a Phase II trial of NV-387 oral gummies targeting Bundibugyo ebolavirus. The initial dose run-in aims to set a tolerable dosing approach for sicker patients before an efficacy evaluation; no results have been presented.
